Various analysts have issued ratings on Integra LifeSciences shares, according to Risers & Fallers.
Here are five things to know:
1. On Feb. 15, six analysts gave the shares a "strong buy" rating and three analysts gave the shares a "buy" rating.
2. Six analysts gave the shares a "neutral" rating.
3. Integra LifeSciences Holdings has a 50-day moving average of $62.57 and 200-day moving average of $62.29.
4. The market cap is $2.05 billion.
5. During the last trading session, the shares were down 0.07 percent.
More articles on devices:
ConforMIS reports Q4, full year results — 12 things to know
Hip, knee orthopedic surgical implants market to reach $33M by 2022: 3 takeaways
National Government Services establishes positive coverage for MIS SI joint fusion: 5 points